These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27068290)

  • 21. Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma.
    Kaya H; Demir M; Taylan M; Sezgi C; Tanrikulu AC; Yilmaz S; Bayram M; Kaplan I; Senyigit A
    Asian Pac J Cancer Prev; 2015; 16(4):1403-7. PubMed ID: 25743806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.
    Koyuncu A; Koksal D; Ozmen O; Demirag F; Bayiz H; Aydogdu K; Berkoglu M
    J Cancer Res Ther; 2015; 11(1):216-22. PubMed ID: 25879365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
    Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
    BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification.
    Urso L; Silic-Benussi M; Boscolo A; Lorenzi M; Bonanno L; Lunardi F; Guarneri V; Calabrese F; Rea F; Conte P; Pasello G
    Cytokine; 2021 Oct; 146():155622. PubMed ID: 34153874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
    Hoda MA; Dong Y; Rozsas A; Klikovits T; Laszlo V; Ghanim B; Stockhammer P; Ozsvar J; Jakopovic M; Samarzija M; Brcic L; Bendek M; Szirtes I; Reid G; Kirschner MB; Kao SC; Opitz I; Weder W; Frauenfelder T; Nguyen-Kim TD; Aigner C; Klepetko W; van Zandwijk N; Berger W; Dome B; Grusch M; Hegedus B
    Eur J Cancer; 2016 Aug; 63():64-73. PubMed ID: 27288871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
    BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
    Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
    Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative lymphocyte-to-monocyte ratio (LMR) could independently predict overall survival of resectable gastric cancer patients.
    Pan YC; Jia ZF; Cao DH; Wu YH; Jiang J; Wen SM; Zhao D; Zhang SL; Cao XY
    Medicine (Baltimore); 2018 Dec; 97(52):e13896. PubMed ID: 30593200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma.
    Meniawy TM; Creaney J; Lake RA; Nowak AK
    Br J Cancer; 2013 Oct; 109(7):1813-20. PubMed ID: 23982605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
    Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M
    Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and prognostic role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and lymphocyte/monocyte ratio in patients with osteosarcoma.
    Yapar A; Tokgöz MA; Yapar D; Atalay İB; Ulucaköy C; Güngör BŞ
    Jt Dis Relat Surg; 2021; 32(2):489-496. PubMed ID: 34145828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis].
    Li B; Zhou CX; Pu YQ; Qiu L; Mei W; Xiong W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Mar; 41(3):168-176. PubMed ID: 37006141
    [No Abstract]   [Full Text] [Related]  

  • 33. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete blood count-based inflammatory score (CBCS) is a novel prognostic marker for gastric cancer patients after curative resection.
    Lin JX; Lin JP; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu R; Zheng CH; Huang CM; Li P
    BMC Cancer; 2020 Jan; 20(1):11. PubMed ID: 31906893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
    Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
    Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.
    Meerang M; Bérard K; Friess M; Bitanihirwe BK; Soltermann A; Vrugt B; Felley-Bosco E; Bueno R; Richards WG; Seifert B; Stahel R; Weder W; Opitz I
    Mol Oncol; 2016 Oct; 10(8):1255-65. PubMed ID: 27378628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of systemic inflammation-based lymphocyte- monocyte ratio in patients with lung cancer: based on a large cohort study.
    Hu P; Shen H; Wang G; Zhang P; Liu Q; Du J
    PLoS One; 2014; 9(9):e108062. PubMed ID: 25275631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
    Kao SC; Vardy J; Chatfield M; Corte P; Pavlakis N; Clarke C; van Zandwijk N; Clarke S
    Clin Lung Cancer; 2013 Jan; 14(1):70-7. PubMed ID: 22658812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma.
    Hutterer GC; Stoeckigt C; Stojakovic T; Jesche J; Eberhard K; Pummer K; Zigeuner R; Pichler M
    Urol Oncol; 2014 Oct; 32(7):1041-8. PubMed ID: 25027686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.